Dan (Kelly) Wang
About Dan (Kelly) Wang
Dan (Kelly) Wang is the Director of Regulatory Science and Strategy for Novel Combinations at BeiGene, with extensive experience in regulatory processes and policy development.
Company
Dan (Kelly) Wang is currently a Director at BeiGene in the Washington DC-Baltimore area. In this role, she focuses on Regulatory Science and Strategy for Novel Combinations.
Title
As Director of Regulatory Science and Strategy for Novel Combinations at BeiGene, Dan Wang specializes in the regulatory aspects of new therapeutic product combinations.
Education and Expertise
Dan Wang holds a Doctor of Philosophy (Ph.D.) in Cell/Cellular and Molecular Pathology from the University of Pittsburgh, spanning from 2004 to 2010. She also earned a Master's degree in Information Science from the same institution between 2013 and 2015. Her extensive expertise includes premarket review processes for various types of medical products and a profound understanding of IT and digital health tools.
Professional Background
Dan Wang has held several significant positions, including a Biologist at the US Food and Drug Administration from 2017 to 2021 and a Scientific Information Specialist at Engility Corporation from 2016 to 2017. She also has research experience as a Research Associate at the University of Pittsburgh School of Medicine from 2011 to 2015. Additionally, she worked on graduate projects in information science at the University of Pittsburgh School of Information Sciences from 2013 to 2015.
Achievements
Wang has played a critical role in numerous initiatives, serving as a champion of a new guidance working group and as an FDA liaison to external policy working groups. Her capabilities include leading reviews and correspondence related to tissue and cellular product policy and managing cross-functional projects effectively.